In this episode, we dive deep into a groundbreaking study exploring the role of cell surface Nucleophosmin 1 (NPM1) in Acute Myeloid Leukemia (AML). Discover how researchers are rethinking NPM1—a protein traditionally known for its intracellular functions—as a novel therapeutic target on the cell surface. We break down the science behind NPM1 mutations, its implications in AML pathogenesis, and how its aberrant localization might open doors to innovative antibody-based therapies. Whether you're a student, researcher, or just a curious mind, this episode offers clear insights into the future of personalized cancer treatment.